Portola Pharmaceuticals Presents Updated Interim Results from Ongoing Phase 2a Study of  Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses  in Heavily Pre-Treated T-Cell Malignancies at ASH 2018